In:
CHIMIA, Swiss Chemical Society, Vol. 74, No. 10 ( 2020-10-28), p. 765-
Abstract:
For over 50 years, Switzerland has been one of the leading countries driving innovation in biotechnology and its industrial applications. Today, some 1,000 biotech companies form a tightly knit, cross-functional network ranging from research through to manufacturing. This network comprises
R & D companies, contract research organizations, and highly specialized advisors and biotech investors. Together, they form an external innovation pool that complements the in-house R & D capacity of the large multi-national pharma companies. A highly effective startup framework, solid
acceleration mechanisms, and innovative investors enable the emergence of a continuous flow of biotech startups that revitalize the industry with new technologies and products supporting drug development and diagnostics.
Type of Medium:
Online Resource
ISSN:
2673-2424
,
0009-4293
DOI:
10.2533/chimia.2020.765
Language:
Unknown
Publisher:
Swiss Chemical Society
Publication Date:
2020
detail.hit.zdb_id:
2179192-2
Permalink